Mikala Egeblad, Ph.D.

Bloomberg Distinguished Professor


Johns Hopkins University School of Medicine
855 N. Wolfe Street, 451 Rangos Bldg


Academic Titles

Bloomberg Distinguished Professor of Tumor Microenvironment


Professor of Cell Biology
Professor of Oncology
Co-Leader, Cancer Invasion and Metastasis Program, Sidney Kimmel Comprehensive Cancer Center

Research Topic

The Egeblad lab studies the contributions of the tumor microenvironment – in which cancer cells arise and live – to therapy responses and metastasis. Solid tumors are abnormally organized tissues that contain not only cancer cells, but also various stromal cell types and extracellular matrix, and these latter components constitute the microenvironment. Communications between the different components of the tumor influence its growth, its response to therapy, and its ability to metastasize. The lab studies the importance of tumor-stroma communications using co-culture assays and mouse models of breast and pancreatic cancer. We use co-culture assays to interrogate signaling pathways involved in communications between cancer cells and specific types of stromal cells (e.g., macrophages, neutrophils and fibroblasts). We use microscopy of tumors in live mice to determine how interactions between cancer and stromal cells or activation of specific signaling pathways influence cellular survival, proliferation and migration. We use bioluminescence and small animal ultrasound to follow tumor progression and regression at the organism level. Our main focus is on the functions of myeloid-derived immune cells, a diverse group of cells that can enhance angiogenesis and metastasis and suppress the response to chemotherapy and the cytotoxic immune responses against tumors. We study how different types of myeloid cells are recruited to tumors and how signals between them and the cancer cells, or other immune cells, influence response to chemotherapy and metastatic spread.


Further Information

Triggering the body’s defenses to fight cancer.Nautilus, November13 (2021)

The Scientist, May 28 (2020)
Scientific American, April 28 (2020)
The Scientist, October 1 (2019)
Oncology Times, January 5 (2018)